{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:50:43Z","timestamp":1792043443645,"version":"4.4.0"},"reference-count":25,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Immunex, a wholly owned subsidiary of Amgen Inc","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We used the Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) data set to examine the impact of presence of enthesitis, dactylitis, nail disease and\/or psoriasis on treatment response in patients with early psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis evaluated the effect of baseline Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index (EI), Leeds Enthesitis Index (LEI), Leeds Dactylitis Index (LDI), modified Nail Psoriasis Severity Index (mNAPSI) scores and body surface area (BSA) on composite outcomes of minimal disease activity (MDA) responses, Psoriatic Arthritis Disease Activity Score (PASDAS) low disease activity (LDA), PASDAS changes and Good Responses and Disease Activity Index for Psoriatic Arthritis (DAPSA) scores at Week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 851 patients completed the SEAM-PsA trial and were included in the analysis. Baseline enthesitis (SPARCC EI&gt;0\u2009vs SPARCC EI=0\u2009or LEI&gt;0\u2009vs LEI=0) was not associated with improved outcomes. Baseline dactylitis (LDI&gt;0\u2009vs LDI=0) was positively associated with improved MDA (OR: 1.4, p=0.0457), PASDAS LDA (OR: 1.8, p=0.0014) and Good Responses (OR: 1.6, p=0.0101) and greater reductions in PASDAS (estimate: \u20130.9, p&lt;0.0001) and DAPSA scores (estimate: \u20133.8, p=0.0155) at Week 24. Similarly, baseline nail disease (mNAPSI &gt;1\u2009vs mNAPSI\u22641) was positively associated with improved MDA (OR: 1.8, p=0.0233) and PASDAS LDA (OR: 1.8, p=0.0168) responses and greater reduction in PASDAS (estimate: \u20130.7, p=0.0005) at Week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Results from our analysis suggest that presence of dactylitis and nail disease, but not enthesitis, are associated with improved outcomes in patients with early PsA who were treated with methotrexate and\/or etanercept.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002366","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T11:25:59Z","timestamp":1658402759000},"page":"e002366","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02376790","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S","family":"Helliwell","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Phillip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kricorian","sequence":"additional","affiliation":[{"name":"Clinical Development, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyrica X H","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Biostatistics, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collier","sequence":"additional","affiliation":[{"name":"Clinical Development, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Centre for Prognosis Studies in The Rheumatic Diseases, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"2025090313572904000_8.2.e002366.1","first-page":"69","article-title":"Psoriasis and psoriatic arthritis. dermatological and rheumatological co-operative clinical report","volume":"146","author":"Biondi Oriente","year":"1989","journal-title":"Acta Derm Venereol Suppl"},{"key":"2025090313572904000_8.2.e002366.2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313572904000_8.2.e002366.3","first-page":"s216","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter","year":"2016","journal-title":"Am J Manag Care"},{"key":"2025090313572904000_8.2.e002366.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"2025090313572904000_8.2.e002366.5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313572904000_8.2.e002366.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"key":"2025090313572904000_8.2.e002366.7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313572904000_8.2.e002366.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"2025090313572904000_8.2.e002366.9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000606"},{"key":"2025090313572904000_8.2.e002366.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"2025090313572904000_8.2.e002366.11","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/acr.23174","article-title":"Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090313572904000_8.2.e002366.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"2025090313572904000_8.2.e002366.13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","article-title":"Assessing disease activity in psoriatic arthritis: a literature review","volume":"6","author":"Tucker","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090313572904000_8.2.e002366.14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00296-019-04480-9","article-title":"Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study","volume":"40","author":"Sunar","year":"2020","journal-title":"Rheumatol Int"},{"key":"2025090313572904000_8.2.e002366.15","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1093\/rheumatology\/keaa042","article-title":"Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management","volume":"59","author":"Mease","year":"2020","journal-title":"Rheumatology"},{"key":"2025090313572904000_8.2.e002366.16","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"key":"2025090313572904000_8.2.e002366.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.10812"},{"key":"2025090313572904000_8.2.e002366.18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/rheumatology\/keab384","article-title":"Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging?","volume":"61","author":"Felbo","year":"2022","journal-title":"Rheumatology"},{"key":"2025090313572904000_8.2.e002366.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140172"},{"key":"2025090313572904000_8.2.e002366.20","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: which is the best instrument to use?","volume":"34","author":"Healy","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313572904000_8.2.e002366.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190923"},{"key":"2025090313572904000_8.2.e002366.22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23 (suppl 1)","author":"McGonagle","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090313572904000_8.2.e002366.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.09.011"},{"key":"2025090313572904000_8.2.e002366.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.06.312","article-title":"25851 efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: results from the MAXIMISE trial","volume":"85(3 suppl)","author":"Gottlieb","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025090313572904000_8.2.e002366.25","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.211037","article-title":"Potential impact of sex and body mass index on response to therapy in psoriatic arthritis: post-hoc analysis of results from the SEAM-PsA trial","author":"Mease","year":"2022","journal-title":"J Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:57:41Z","timestamp":1756933061000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,21]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/rmdopen-2022-002366"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002366","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}